The Evolving Landscape of Molecular Alterations in NSCLC: Optimizing Testing and Treatment to Improve Outcomes

home / insights / evolving-landscape-of-molecular-alterations-in-nsclc-optimizing-testing-and-treatment

Expert oncologists share updates on the testing and treatment of molecular alterations in advanced non-small cell lung cancer.

Expert on lung cancer

EP. 1: Overview of Actionable Mutations and Molecular Profiling in NSCLC

Meghan J. Mooradian, MD
April 15th 2022
Expert on lung cancer

EP. 2: Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer

Meghan J. Mooradian, MD
April 15th 2022
Expert on NSCLC

EP. 3: Is There a Role for IO Therapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements?

Meghan J. Mooradian, MD
April 22nd 2022
Expert on NSCLC

EP. 4: Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

Meghan J. Mooradian, MD
April 22nd 2022
Expert on NSCLC

EP. 5: IO Therapy in NSCLC With Concomitant KRAS/TP53 Mutations

Meghan J. Mooradian, MD
April 29th 2022
Expert on lung cancer

EP. 6: Molecular Testing in Advanced NSCLC: Recommended Targets and Methods

Ticiana A. Leal, MD
May 11th 2022
Expert on lung cancer

EP. 7: Optimizing Use of Molecular Testing in Advanced NSCLC

Ticiana A. Leal, MD
May 11th 2022
Expert on lung cancer

EP. 8: Overcoming Barriers to Molecular Testing in NSCLC

Ticiana A. Leal, MD
May 18th 2022
Expert on lung cancer

EP. 9: Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

Ticiana A. Leal, MD
May 18th 2022
Expert on lung cancer

EP. 10: Immunotherapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

May 25th 2022
Expert on lung cancer

EP. 11: Immunotherapy in NSCLC With Concomitant KRAS/TP53 Mutations

Ticiana A. Leal, MD
May 25th 2022
Expert on lung cancer

EP. 12: Testing Strategies for Actionable Mutations in Non–Small Cell Lung Cancer

John Heymach, MD, PhD
June 13th 2022
Expert on lung cancer

EP. 13: NSCLC: The Role of Liquid Biopsy in Molecular Testing and Treatment Decision-Making

John Heymach, MD, PhD
June 13th 2022
Expert on lung cancer

EP. 14: Overcoming Barriers to Molecular Profiling in NSCLC Management

John Heymach, MD, PhD
June 20th 2022
Expert on lung cancer

EP. 15: Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?

John Heymach, MD, PhD
June 20th 2022
Expert on lung cancer

EP. 16: I/O Therapy in KRAS-Mutant NSCLC With Concomitant STK11 or KEAP1 Mutations

John Heymach, MD, PhD
June 27th 2022
Expert on lung cancer

EP. 17: NSCLC: Immunotherapy in Patients With Concomitant KRAS/TP53 Mutations

John Heymach, MD, PhD
June 27th 2022